Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 41

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 41
---
 the book value of your shares.

The public offering price of our common stock is substantially higher than the net
tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. Assuming
the sale of 3,849,114 shares of our common stock in this offering, based on the assumed public offering price of $12.99 per share, which was the last reported sale price of our common stock on Nasdaq Capital Market on December 9, 2025, and
net tangible book value per share of our common stock of $(2.94) as of September 30, 2025, if you purchase shares in this offering, you will suffer immediate and substantial dilution of $(8.87) per share in the net tangible book value of common
stock purchased. To the extent shares are issued under outstanding options or warrants, you will incur further dilution. See “Dilution” for a more detailed description of the dilution to new investors in the offering.

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we may at any time, including during the pendency of this offering, offer additional shares of our common
stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is
less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our
common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.

S-5

CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS

This prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and other written and oral
statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). You can identify these forward-looking statements by the fact they use words such as “could,” “